BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Integral Molecular, Inc. and Crystal Bioscience Announce Research Collaboration to Develop Novel GPCR and Ion Channel Antibodies


11/16/2012 9:01:13 AM

PHILADELPHIA & EMERYVILLE, Calif.--(BUSINESS WIRE)--Crystal Bioscience and Integral Molecular have launched a research collaboration to generate panels of chicken monoclonal antibodies against undisclosed therapeutic GPCR and ion channel targets. The collaboration will leverage the synergy between Integral Molecular's Lipoparticle technology for immunization with native conformation multispanning membrane proteins and Crystal's GEM technology for the recovery of monoclonal antibodies against otherwise conserved proteins raised in immunized chickens. “We are excited to be working with Crystal Bioscience to develop antibodies in alternative species where there is increased likelihood of success in eliciting antibodies against epitopes conserved in mammals,” said Dr. Joseph Rucker, Director of Research and Development at Integral Molecular. “We believe that this powerful combination of technologies for immunization and screening will culminate in the ability to produce antibodies against therapeutic targets that have been historically difficult to work with due to both their conformational complexity and high conservation.”

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES